# Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

> **NCT05827549** · PHASE2 · RECRUITING · sponsor: **Ho Joon Im** · enrollment: 90 (estimated)

## Conditions studied

- Acute Lymphoid Leukemia

## Interventions

- **DRUG:** Reinduction(4weeks)
- **DRUG:** Cosolodation 1st(3weeks)
- **DRUG:** Consolidation 2nd(3weeks)
- **DRUG:** Blinatumomab 1st(High Risk Group)_4 Weeks
- **DRUG:** Blinatumomab 2nd (High Risk Group)_4 Weeks
- **DRUG:** Blinatumomab-Salvage 1st (Very High Risk Group)_4 Weeks
- **DRUG:** Blinatumomab-Salvage 2nd (Very High Risk Group)_4 Weeks
- **DRUG:** Intensification course
- **DRUG:** Maintenance(12 Weeks/Cycle)
- **PROCEDURE:** Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT05827549
- **Lead sponsor:** Ho Joon Im
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-04
- **Primary completion:** 2032-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-06-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05827549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05827549, "Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05827549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*